论文部分内容阅读
目的:观察氨鲁米特(lentaron)治疗绝经后晚期和复发性乳腺癌患者的疗效和副作用。方法:2013年1月~2016年1月对17例复发性乳腺癌患者给予氨鲁米特 250 mg口服,一次250 mg,一日2次,两周以后一日3-4次,但一日不超过1g,至少2个月。结果:通过为期2个月的治疗以后,本研究完全缓解0例,部分缓解5例(29.41%),稳定11例(64.71%),进展1例(5.88%)。治疗过程中,5例患者出现注射位置硬结、瘙痒现象,2例患者出现轻度的恶心呕吐,不良反应发生率为41.18%。结论:针对绝经后乳腺癌患者,采用氨鲁米特治疗具有较为理想的临床疗效,并且不会引发严重的不良反应,患者耐受性良好,其可以作为转移性乳腺癌、无法耐受化疗与手术的原发性乳腺癌的治疗方案,对患者生活质量的改善具有重要的促进作用。
OBJECTIVE: To observe the efficacy and side effects of lentaron in the treatment of patients with advanced and recurrent breast cancer after menopause. METHODS: From January 2013 to January 2016, 17 patients with recurrent breast cancer were given 250 mg aminoritidine 250 mg orally twice a day for two to four days on the 1st, Not more than 1g, at least 2 months. Results: After 2 months of treatment, the study completely relieved 0 cases, partially relieved in 5 cases (29.41%), stabilized in 11 cases (64.71%), and progressed in 1 case (5.88%). During the course of treatment, 5 patients showed induration and pruritus at the site of injection, and mild nausea and vomiting occurred in 2 patients. The incidence of adverse reactions was 41.18%. Conclusion: For patients with postmenopausal breast cancer, the treatment with aminoglutethimide has the best clinical efficacy and does not cause serious adverse reactions. The patients are well tolerated. They can be used as metastatic breast cancer and can not tolerate chemotherapy and Surgical treatment of primary breast cancer, the quality of life of patients with an important role in promoting.